



ADVANCED HEALTH LIMITED

(Incorporated in the Republic of South Africa)

(Registration number 2013/059246/06)

("the Company" or "Advanced")

ISIN Code: ZAE000189049 JSE Code: AVL

REVIEWED CONDENSED CONSOLIDATED ANNUAL FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2019

HIGHLIGHTS

- Revenue increased by 18% to R481.7 million (2018: R406.6 million).
- EBITDA improved by greater than 100% to R17.6 million (2018: Negative EBITDA R0.1 million).
- Headline loss per share from both continuing and discontinued operations improved by 23% to 10.84 cents (2018: 14.12 cents).
- Loss for the year increased by 5% to R37.9 million (2018: R36.2 million).
- Loss attributable to disposal of Coffs Harbour Day Hospital amounts to R13.5 million (2018: R5.6 million).
- Cash generated from operations increased by greater than 100% to R15.6 million (2018: R5.8 million).

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

All figures in R'000	Note	Reviewed Year ended 30 June 2019	Audited Year ended 30 June 2018
ASSETS			
Non-current assets		424 655	418 273
Property, plant and equipment	6	259 599	282 744
Goodwill		29 669	30 185
Intangible assets	7	30 777	33 520
Operating lease asset	8	476	478
Other financial assets	9	28 285	10 586
Deferred taxation	10	75 849	60 760
Current assets		106 544	96 709
Inventories		14 442	13 958
Trade and other receivables	11	37 763	33 393
Operating lease asset	8	3 682	5 634
Other financial assets	9	5 268	2 298
Current tax receivable		144	107
Cash and cash equivalents	12	45 245	41 319
Total assets		531 199	514 982
EQUITY AND LIABILITIES			
Capital and reserves		145 818	193 831
Stated capital	2	221 956	221 956
Share-based payment reserve	13	1 283	1 880
Foreign currency translation reserve	14	32 108	34 363
Retained earnings		(109 529)	(64 368)
Non-controlling interest	3	64 142	53 459
Total equity		209 960	247 290
Non-current liabilities		216 531	170 084
Other financial liabilities	15	177 465	127 495
Finance lease obligations	16	12 428	19 497
Operating lease liability	8	25 531	22 101
Provisions		1 107	991
Current liabilities		104 708	97 608
Other financial liabilities	15	22 706	18 239
Finance lease obligations	16	8 422	18 718
Trade and other payables		48 941	45 919
Provisions		7 661	7 366
Current tax payable	17	3 167	5 000
Operating lease liabilities	8	2 533	2 366
Bank overdraft	12	11 278	-
Total equity and liabilities		531 199	514 982

Notes to statement of financial position

Total number of shares in issue ('000)	287 988	287 988
Net asset value per share (cents)	72.91	85.87
Net tangible asset value per share (cents)	51.92	63.75

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

All figures in R'000	Note	Reviewed Year ended 30 June 2019	Restated Year ended 30 June 2018*
Revenue	18	481 677	406 636
Cost of sales	18	(228 691)	(199 304)
Gross profit		252 986	207 332
EBITDA (earnings before interest, impairment, tax, depreciation and amortisation)	19	17 594	(126)
Investment income		901	807
Depreciation and amortisation	20	(34 477)	(32 451)
Finance costs		(16 370)	(14 702)
Loss before taxation from continuing operations		(32 352)	(46 472)
Taxation		7 823	15 824
Loss for the year from continuing operations		(24 529)	(30 648)
Loss from discontinued operations	5	(13 452)	(5 597)
Loss for the year		(37 981)	(36 245)
Other comprehensive (expense) / income for the year, net of tax	14	(3 600)	6 500
Total comprehensive loss for the year		(41 581)	(29 745)
Loss attributable to:		(37 981)	(36 245)
Owners of the parent – continuing operations		(31 211)	(33 991)
Owners of the parent – discontinued operations		(13 452)	(5 597)
Non-controlling interest		6 682	3 343
Total comprehensive loss attributable to:		(41 581)	(29 745)
Owners of the parent – continuing operations		(33 466)	(28 526)
Owners of the parent – discontinued operations		(13 452)	(5 597)
Non-controlling interest		5 337	4 378

Per share information:

Loss per share (cents)	(15.51)	(14.12)
• From continuing operations	(10.84)	(12.12)
• From discontinued operation	(4.67)	(2.00)
Diluted loss per share (cents)	(15.51)	(14.12)
• From continuing operations	(10.84)	(12.12)
• From discontinued operation	(4.67)	(2.00)

*Comparative figures have been re-presented to reflect the effect of the discontinued operations

	Reviewed Year ended 30 June 2019	Restated* Year ended 30 June 2018
All figures in R'000		
Notes to the statement of comprehensive income		
Headline loss for the year attributable to ordinary shareholders from continuing operations		
Headline loss per share (cents)	(10.84)	(12.13)
Diluted headline loss per share (cents)	(10.84)	(12.13)
- Total number of shares in issue ('000)	287 988	287 988
- Weighted average number of shares ('000)	287 988	280 351
Reconciliation of headline earnings calculation:		
Loss for the year attributable to ordinary shareholders from continuing operations	(31 211)	(33 991)
Profit on sale of property, plant and equipment	-	(10)
Loss on sale of subsidiary	-	-
Tax effects of adjustments	-	3
Headline loss for the year attributable to ordinary shareholders	(31 211)	(33 998)
Headline loss for the year attributable to ordinary shareholders from discontinued operations:		
Headline loss per share (cents)	-	(1.99)
Diluted headline loss per share (cents)	-	(1.99)
- Total number of shares in issue ('000)	287 988	287 988
- Weighted average number of shares ('000)	287 988	280 351
Reconciliation of headline earnings calculation:		
Loss for the year attributable to ordinary shareholders from discontinued operations	(13 452)	(5 597)
Loss on sale of subsidiary	15 513	-
Tax effects of adjustments	(2 061)	-
Headline loss for the year attributable to ordinary shareholders	-	(5 597)

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

All figures in R'000	Note	Reviewed Year ended 30 June 2019	Audited Year ended 30 June 2018
Cash flows used in operating activities			
Cash generated by operations	12	15 577	5 772
Investment income		901	807
Finance cost		(10 363)	(13 895)
Taxation paid	17	(11 854)	(5 863)
Net cash used in operating activities		(5 739)	(13 179)
Cash flows from investing activities			
Acquisition of property, plant and equipment	6	(15 814)	(54 104)
Proceeds on the sale of property, plant and equipment		1 976	1 693
Acquisition of intangible assets	7	(1 656)	(1 658)
Proceeds on disposal of Coffs Harbour Day Hospital	5	512	-
Acquisition of 100 % shares in Madison Day Surgery		-	(8 439)
Financial assets advanced	9	(16 882)	(4 147)
Financial assets received	9	-	3 126
Net cash used in investing activities		(31 864)	(63 529)
Cash flows from financing activities			
Issue of shares in subsidiary	3	8 176	20 232
Financial liabilities raised	15	63 424	97 648
Financial liabilities repaid	15	(9 395)	(32 964)
Dividends paid – non-controlling interest		(8 346)	(5 958)
Finance costs		(596)	(807)
Finance lease payments	16	(21 464)	(1 422)
Net cash from financing activities		31 799	76 729
Net (decrease) / increase in cash and cash equivalents		(5 804)	21
Cash and cash equivalents at beginning of year		41 319	40 483
Cash and cash equivalents on date of disposal of Coffs		(517)	-
Effect of foreign currency translation		(1 031)	815
Cash and cash equivalents at end of year	12	33 967	41 319

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

	Net stated capital	Share based payment reserve	Foreign currency translation reserve	Retained earnings	Non- controlling interest	Total equity
	R'000	R'000	R'000	R'000	R'000	R'000
Audited Balance at 1 July 2017	137 378	4 016	28 898	(28 417)	43 507	185 382
Loss for the year	-	-	-	(39 588)	3 343	(36 245)
Other comprehensive income for the year	-	-	5 465	-	1 035	6 500
Share-based payment expense	-	1 501	-	-	-	1 501
Transfer between reserves	-	(3 637)	-	3 637	-	-
Change in interest of subsidiary	-	-	-	-	11 532	11 532
Dividends	-	-	-	-	(5 958)	(5 958)
Issue of shares	84 578	-	-	-	-	84 578
Audited Balance at 1 July 2018	221 956	1 880	34 363	(64 368)	53 459	247 290
Loss for the year	-	-	-	(44 663)	6 682	(37 981)
Other comprehensive loss for the year	-	-	(2 255)	-	(1 345)	(3 600)
Share-based payment expense	-	306	-	-	-	306
Transfer between reserves	-	(903)	-	903	-	-
Change in interest of subsidiary	-	-	-	(1 401)	893	(508)
Dividends *	-	-	-	-	(8 346)	(8 346)
Issue of shares	-	-	-	-	12 799	12 799
Reviewed balance at 30 June 2019	221 956	1 283	32 108	(109 529)	64 142	209 960
Note	2	13	14		3	

*Dividends were declared by the subsidiaries of the Group amounting to R12.8 million (2018: R5.9 million)

NOTES TO THE REVIEWED PROVISIONAL CONDENSED CONSOLIDATED ANNUAL FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2019

1. BASIS OF PREPARATION

The reviewed provisional consolidated financial statements are prepared in accordance with the Listings Requirements of the JSE Limited for provisional reports, and the requirements of the Companies Act applicable to summary financial statements. The JSE Listings Requirements require provisional reports to be prepared in accordance with the framework concepts and the measurement and recognition requirements of International Financial Reporting Standards (IFRS) and Financial Pronouncements as issued by the Financial Reporting Standards Council and to also, as a minimum, contain the information required by IAS 34 Interim Financial Reporting. The accounting policies and computations applied in the preparation of the summary consolidated financial statements from which the summary financial statements were derived are in terms of IFRS and are consistent with those accounting policies and computations applied in the preparation of the previous consolidated annual financial statements except for the effect of the mandatory adoption of IFRS 15 : Revenue from Contracts with Customers and IFRS 9 : Financial Instruments with effect from 1 July 2018. The adoption of IFRS 9 and IFRS 15 did not have a significant impact on the amounts recognised or disclosed in the reviewed condensed consolidated annual financial statements therefore Advanced elected not to restate prior years.

The reviewed condensed consolidated financial statements have been prepared under the supervision of CP Snyman CA (SA) in his capacity as Chief Financial Officer.

The reviewed condensed consolidated financial statements have been reviewed by the Group's Auditors, Mazars who have issued an unmodified review opinion, available for inspection at the Company's registered office.

The board of directors of Advanced take full responsibility for the preparation of the reviewed condensed consolidated financial statements for the year ended 30 June 2019.

The reviewed condensed consolidated financial statements for the year were authorised for issue by the board of directors on 27 August 2019.

2. STATED CAPITAL

The issued stated capital of Advanced is 287 988 433 shares amounting to R221 956 000 (June 2018: 287 988 433 amounting to R221 956 000) being the legal entity listed on the JSE AltX.

Reconciliation of stated capital

	Number of shares '000	Stated capital R'000	Equity reserve* R'000	Group stated capital R'000
Balance as at 1 July 2018	287 988	310 423	(88 467)	221 956
Balance as at 30 June 2019	287 988	310 423	(88 467)	221 956

* The equity reserve arose in 2014 as a result of accounting for the reverse acquisition in terms of IFRS 3 Business Combination

3. TRANSACTIONS WITH NON-CONTROLLING INTEREST

On 2 April 2019 and 26 June 2019, Advanced's Australian subsidiary, Presmed Australia (Pty) Limited "Presmed Group" issued 40 000 shares in total to related parties reducing Advanced's shareholding to 86.51% from 90.84%.

Consideration received from non-controlling interests during the year in Australia was R10.3 million and South Africa R2.5 million getting to a total of R12.8 million which corresponds to the issue of shares to non-controlling interest.

4. SEGMENTAL REPORTING

Segment information is presented only at Group level, where it is most meaningful. Operating segments are identified on the basis of internal reports about components of the Group that are regularly reviewed by the Chief Operating Decision-Maker in order to allocate resources to the segment and to assess its performance. The segments are based on the geographical location with corporate including Advanced “the company”.

	Reviewed Year ended June-19	Audited Year ended June-18
	R'000	R'000
REVENUE	481 677	406 636
South Africa	162 237	117 430
Australia	319 440	289 206
INTEREST INCOME	901	807
South Africa	516	592
Australia	385	215
INTEREST EXPENSE	16 370	14 702
South Africa	12 784	10 580
Australia	2 990	3 315
Corporate	596	807
DEPRECIATION & AMORTISATION	34 477	32 451
South Africa	19 888	17 915
Australia	13 986	13 869
Corporate	603	667
(LOSS)/PROFIT FOR THE YEAR	(37 981)	(36 245)
South Africa	(45 984)	(42 758)
Australia	9 907	7 544
Corporate	(1 904)	(1 031)

SEGMENT ASSETS	531 199	514 982
South Africa	280 853	266 663
Australia	241 194	237 900
Corporate	9 152	10 419
SEGMENT LIABILITIES	321 239	267 692
South Africa	221 166	162 260
Australia	94 439	98 901
Corporate	5 634	6 531

The revenue from external parties and all other items of income, expenses, profits and losses reported in the segment report are measured in a manner consistent with that in the statement of comprehensive income.

5. DISCONTINUED OPERATIONS

During the financial year, Presmed Group divested from its loss-making subsidiary, Coffs Harbour Day Hospital (Proprietary) Limited "Coffs". On 29 March 2019 the subsidiary was sold and is reported as a discontinued operation. Financial information relating to the discontinued operation for the period to the date of disposal is set out below.

Financial performance and cash flow information

The financial performance and cash flow information presented are for the 9 months ended 29 March 2019 and the year ended 30 June 2018 and have been translated using the exchange rates applicable at the respective dates.

	2019 R'000	2018 R'000
(a) Financial information		
Revenue	4 699	2 654
Expenses	(11 062)	(10 650)
Loss before income tax	(6 363)	(7 996)
Income tax benefit	2 061	2 399
Loss after income tax of discontinued operation	(4 302)	(5 597)
Loss on sale of the subsidiary after income tax (see section below)	(9 150)	-
Loss from discontinued operation	(13 452)	(5 597)
(b) Cash flow information		
Net cash outflow from operating activities	(5 509)	(7 911)
Net cash outflow from investing activities	(2 357)	(2 975)
Net cash inflow from financing activities	-	-
Net decrease in cash generated by the subsidiary	(7 866)	(10 886)
(c) Carrying amounts of assets and liabilities as at the date of sale (29 March 2019)		
	R'000	
Cash and cash equivalents	517	
Trade and other receivables	631	
Property, plant and equipment	9 394	
Deferred tax assets	4 540	
Total Assets	15 082	
Trade and other payables	(185)	
Finance lease payables	(788)	
Borrowings	(4 447)	
Total Liabilities	(5 420)	
Net assets	9 662	
(d) Gain on disposal		
Carrying amount of net assets sold (c)	(9 662)	
Cash consideration received	512	
Loss on sale before income tax	(9 150)	

6. PROPERTY, PLANT AND EQUIPMENT

During the year, the Group incurred costs amounting to R15.8 million for capital expenditure. A total of R2 million was incurred in Australia while R13.8 million related to South Africa with the bulk relating to Harbour Bay Surgical Centre in Simon's Town where R4 million was spent.

7. INTANGIBLE ASSETS

The Group purchased additional licences amounting to R1.7 million.

8. OPERATING LEASE ASSETS AND LIABILITIES

The operating lease assets and liabilities relate to the lease straight lining required by IFRS. The additional new facilities also contributed to the increase in the lease assets and liabilities.

9. OTHER FINANCIAL ASSETS

Other financial assets increased due to a loan advanced amounting to R3.9 million in Presmed Group. Further Presmed Group acquired a 19% interest in an investment for a total consideration of R13 million. The 19% interest was accounted for as an investment, as the Presmed Group has no significant influence over this investment – the extent of ownership is not significant relative to other shareholdings (the acquisition is not categorisable in terms of the JSE Listings Requirements).

10. DEFERRED TAX

Deferred tax increased during the period under review due to the tax losses incurred by the Group for the year ended 30 June 2019. These losses will be utilised when the Group starts generating profits. The increase in the trend of patient numbers and the support from the medical schemes indicate that the deferred tax asset will be recovered.

11. TRADE AND OTHER RECEIVABLES

Trade and other receivables increased in South Africa while Presmed Group remained fairly constant. The increase in trade receivables in South Africa is mainly attributed to revenue growth of 38%.

12. CASH AND CASH EQUIVALENTS

There has been a decrease in cash and cash equivalents as compared to June 2018. The Group has engaged less in investing activities and more emphasis has been placed on increases in cash generated from operations. Advanced is at present less reliant on debt to fund its day to day operations. Presmed Group obtained an overdraft facility from the Bank of Queensland. As at the reporting date, an amount of R11.2 million has been used.

13. SHARE BASED PAYMENT RESERVE

As at 30 June 2019, share option scheme 4 expired. This led to the transfer of the share-based payment reserve to retained earnings as disclosed on the Statement of Changes in Equity.

14. FOREIGN CURRENCY TRANSLATION RESERVE

The Foreign Currency Translation Reserve has decreased as a result of the strengthening of the South African Rand. The rate has fluctuated between AUD1: R9.8912 and AUD1: R10.1426.

15. OTHER FINANCIAL LIABILITIES

The movements in the current and non-current other financial liabilities are due to additional loans obtained in South Africa from Eenhede Konsultante and other financial institutions.

16. FINANCE LEASE OBLIGATIONS

Additional finance leases in Australia relating to Medical Equipment amounting to R5.3 million were obtained in the 2019 financial year. Finance lease payments amounting to R21.5 million were incurred with R1.7 million relating to South Africa.

17. CURRENT TAX PAYABLE

Tax payable decreased by 37% to R3.2 million. This is due to a combination of tax due to both Australian authorities and South Africa authorities. During the year a total of R11.9 million was paid over in cash.

18. REVENUE & COST OF SALES

Total revenue increased by 18% to R481.7 million (2018: R406.6 million). This is mainly due to the number of cases that increased by 21%. Revenue in South Africa increased by 38% while Presmed Group's revenue increased by 10%.

	2019 R'000	2018 R'000
Rendering of services		
Included in revenue from contracts with patients:		
Theatre / accommodation fees / facility fees	407 317	360 664
Equipment and fixed fees*	18 819	6 642
	426 136	367 306
Sale of goods		
Drug revenue and gases	55 541	39 330
Total Revenue	481 677	406 636

* Includes dental income and fee adjustments

Revenue from rendering of services and sale of goods are all recognised at a point in time. The Group's principal activities to generate its revenue is to provide same day healthcare facilities. (Refer to note 4 for segmental information that also discloses the revenue disaggregation per geographical location). There is no significant financing component within the payment terms of patient accounts.

19. EBITDA

EBITDA improved from the prior year from a negative to a positive amount. Although the total operating expenses increased from the prior year this was lower than the increase in revenue. This coupled with a 3% improvement in Gross Profit led to the improvement in EBITDA.

20. DEPRECIATION AND AMORTISATION

The increase in depreciation and amortisation relates to the property, plant and equipment purchased during the year.

21. RELATED PARTIES

During the year ended 30 June 2019, certain subsidiaries, in the ordinary course of business, entered into loans and transactions with related parties under terms that are no less favourable than those arranged with third parties.

22. SUBSEQUENT EVENTS

The directors are not aware of any significant matter or circumstance arising since the end of the financial year, not otherwise dealt with in this report, which significantly affect the financial position of the company or the results of its operations to the date of this report.

23. IMPACT OF FIRST-TIME ADOPTION OF IFRS 9 AND IFRS 15

IFRS 9

IFRS 9 introduces new classification categories for financial instruments. Under IFRS 9, financial assets are classified by reference to the business model within which they are held and their contractual cash flow characteristics, while the classification of financial liabilities remains largely the same as that under IAS 39. There have been no changes to the classification, and therefore the measurement criteria, of financial assets and

financial liabilities, except for the naming conventions. Loans and Receivables are now called financial assets at amortised cost. The adoption of IFRS 9 has also led to the change in the calculation of impairment of trade and other receivables from the incurred credit loss model to the expected credit loss model (ECL).

The Group's impairment of trade receivables using the incurred loss model under IAS 39 for the year ended 30 June 2018 was R1.04 million. The ECLs for the year ending 30 June 2018 under IFRS 9 was calculated to be R0.63 million. The difference was considered to be immaterial and thus not been processed as an adjustment to retained earnings using the modified retrospective approach. The ECLs for the year ending 30 June 2019 amounts to R0.26 million.

IFRS 15

IFRS 15 establishes a comprehensive framework for determining whether, how much and when revenue is recognised. It replaced IAS 18 – Revenue and related interpretations. Under IFRS 15, revenue is recognised when a customer obtains control of the goods or services. Determining the timing of the transfer of control – at a point in time or over time.

The Group has adopted IFRS 15 using the cumulative effect method (with practical expedients), with the effect of initially applying this standard recognised at the date of initial application (i.e. 1 July 2018). The Group has taken advantage of the practical exemption not to account for significant financing components where the time difference between receiving consideration and transferring controls of goods and services is one year or less. Accordingly, the information presented for 2018 has not been restated – i.e. it is presented, as previously reported, under IAS 18. Additionally, the disclosure requirements in IFRS 15 have not generally been applied to comparative information.

EXCHANGE RATES

The following exchange rates were used in foreign interest and foreign transactions during the periods:

Rand/Australian Dollar	30 June 2019	29 March 2019	30 June 2018
Closing rate	9.8912	10.2365	10.1426
Average rate	10.14814	10.17533	9.97452

INVESTOR PRESENTATION

There will be an investor presentation on 29 August 2019 and the presentation will be available on the Company's website, hosted at www.advancedhealth.co.za.

COMMENTARY

INTRODUCTION

Advanced continues to establish itself as a leader in day surgery in Australia and South Africa. The Group has positioned itself to fill the gap for day surgery, a growing market segment as a result of exciting developments in medical technology. Medical schemes are increasingly aligning their benefit structures to favour day hospitals where appropriate, with greater traction towards day hospitals as a cost-effective option for surgical procedures.

FINANCIAL RESULTS

The loss reported in the year ended June 2019 does not reflect the encouraging changes in day-hospital utilisation experienced in South Africa. Management is optimistic that the longer-than-anticipated settling-in period of the eight-day hospitals that were commissioned in a relatively short period of time is drawing to a close.

The Australian business, in which Advanced holds an 86.51% interest, contributed 66% to revenue, which is in line with the prior year, and increased profit to R9.9 million (2018: R7.5 million). At group level, revenue increased by 18% to R481.7 million from R406.6 million in the prior year.

OVERVIEW

Australia

In a very competitive healthcare market, Presmed Group has again performed stronger than last year and exceeded expectations at all of its day hospitals for the financial year ending June 2019.

As part of its ongoing strategy to grow the Company, Presmed Group acquired a minor strategic shareholding in Metwest Eye Centre in April 2019, a successful day hospital in the north-west of Sydney.

It is noted, that in March 2019, due to insufficient doctor surgeon support, a decision was made to close the one theatre loss making day clinic in Coffs which had been operational for just over one year.

The Presmed Group continues its emphasis on strengthening its financial position with its current business entities, with a focus on increased surgery throughput and ongoing strong cost controls, good cash collections and operational efficiencies.

Chatswood Private Hospital (CPH), Presmed Group's largest facility, was recently represented at the World Association of Eye Hospital (WAEH) conference, with recognition that Presmed Group is setting premium clinical and functionality standards within our day hospital market. CPH is the only private hospital in Australia to receive membership of the prestigious WAEH.

South Africa

Advanced now operates ten facilities in South Africa. Management remains focussed on marketing strategies aimed at growing patient numbers and increasing earnings. Equipment purchases have decreased compared to historic levels, which should impact positively on cash flow. The latest hospital, Harbour Bay Surgical Centre in Simon's Town, is expected to become operational in October 2019.

DIVIDEND DECLARATION

No dividend is proposed or recommended for the year ended 30 June 2019.

PROSPECTS

Advanced is firmly on track to achieve its aim of growing its footprint of independent, quality and cost-effective day-hospitals, to the benefit of patients, doctors, staff and medical schemes.

In South Africa the group will focus on achieving stability in new facilities and ensuring they become profitable.

Presmed Group's strategy remains to grow and increase its portfolio by acquiring strategic investments in profitable day hospitals aligned to its core business.

Investors are reminded that day hospitals are long term investments and the settling-in periods varies from facility to facility.

Any forward-looking statements in this announcement have not been reviewed and reported on by the Group's Auditors.

CHANGES TO THE BOARD

Mr Carel Petrus Snyman has resigned as Chief Financial Officer with effect from 31 October 2019. The appointment of a new Chief Financial Officer will be done in due course. Mr Gerhardus Jacobus van Emmenis was appointed as Chief Executive Officer with effect from 1 August 2019.

Mr Frans Andre van Hoogstraten stepped down as chairman of the board and that Mr Carl Alfred Grillenberger, current non-executive director was appointed as chairman of the board with effect from 28 August 2019. Mr Frans Andre van Hoogstraten remains a member of the board as lead independent non-executive director.

On behalf of the board

FA van Hoogstraten
Chairman
27 August 2019

GJ van Emmenis
Chief Executive Officer

CP Snyman
Chief Financial Officer

CORPORATE INFORMATION

Advanced Health Limited
(Incorporated in the Republic of South Africa)
Registration number: 2013/059246/06
ISIN: ZAE000189049 JSE Code: AVL

Registered Address:
Building 2, Walker Creek Office Park
90 Florence Ribeiro Avenue
Muckleneuk
0002
Postnet Suite 668, Private Bag X1
The Willows, 0041

As at 29 August 2019 – the directors of Advanced are as listed below:

Executive directors

GJ van Emmenis (Chief Executive Officer)
CP Snyman (Chief Financial Officer)
MC Resnik# (Chief Operational Officer Australia)
D Goss-Ross (Alternate)

Non-Executive Directors

FA van Hoogstraten (Lead Independent)
CA Grillenberger (Chairman)
PJ Jaffe #
CJPG van Zyl
Dr WT Mthembu
Dr J Oelofse
YJ Visser (Alternate)

Australian

Company Secretary: M Janse van Rensburg
Auditors: Mazars
Transfer Secretaries: Link Market Services Proprietary Limited

Date of announcement: 29 August 2019

Designated Advisor
Grindrod Bank Limited

